TriSalus Life Sciences, Inc. TLSI Allowance for Doubtful Accounts

Allowance for Doubtful Accounts at other companies

Boston ScientificBSX

——

InfuSystem HoldingsINFU

——

Other financials

Income statement

See full

Revenue$8.9M-2.9%

Gross profit$7.7M0.0%

Operating income-$8.4M-14.8%

Net income$1.5M+115%

EPS (diluted)$0.03+108%

Balance sheet

See full

Cash & equivalents$56.6M+324%

Total debt$33.1M+4.4%

Total equity$12.8M+137%

Total assets$71.0M+148%

Cash flow

See full

Operating cash flow-$6.5M-44.0%

CapEx$141.0K-81.3%

Free cash flow-$6.6M-26.0%

Valuation

See full

Market cap$279.45M+49.6%

Enterprise value$255.97M+33.6%

P/S6.2×+1.0×

Profitability

See full

Gross margin85.1%-0.5pp

Operating margin-62.4%-16.8pp

Net margin-60.9%-13.4pp

FCF margin-45.2%-16.8pp

Returns & leverage

See full

Return on equity253.3%—

Debt / equity2.6×—

Current ratio5.8×+3.6×

Where this comes from

Reported directly by TriSalus Life Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s allowance for doubtful accounts.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s allowance for doubtful accounts?: TriSalus Life Sciences, Inc. (TLSI) reported allowance for doubtful accounts of $76K in Q1 2026.
How has TriSalus Life Sciences, Inc.'s allowance for doubtful accounts changed year-over-year?: TriSalus Life Sciences, Inc.'s allowance for doubtful accounts decreased by 48.6% year-over-year, from $148K to $76K.